Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial. Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Lam E, Pohlmann H, Wallström E Mult Scler Relat Disord. 2014 Nov; 3(6):752. Epub 2014 Nov 21. PMID: 25891589. Abstract CommentRecommendBookmarkWatch